Things you can point at your own business this week. Not case studies, and not commentary on the state of the industry.
CVS Health puts the GLP-1 break-even price for US health plans at about $350 a month. The drugs are saving medical costs, just not enough to pay for themselves yet. Why patient selection, outcomes-based pricing and persistence now decide reimbursement.

Generic semaglutide arrived in India in March 2026. Novo cut prices, but it also added partner brands and pointed to new formulations. What a blockbuster brand can defend by changing how it competes, not just what it charges.

Abu Dhabi announced five life sciences collaborations at the Future Health Summit. Announcements are not advantage. What decides it is whether the capabilities underneath them can deliver a defined study reliably, and earn the second mandate as well as the first.

Nothing under that filter yet.